Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: Comparing primary and secondary prevention strategies

Quality and Safety in Health Care

Volumn 15, Issue 5, 2006, Pages 339-343

  Gemmell, I ^a   Heller, R F ^a   Payne, K ^a   Edwards, R ^a   Roland, M ^a   Durrington, P ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; HEALTH PROGRAM; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; NATIONAL HEALTH SERVICE; PREVALENCE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; UNITED KINGDOM;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CORONARY DISEASE; FEMALE; GREAT BRITAIN; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POPULATION SURVEILLANCE; PREVALENCE; PRIMARY HEALTH CARE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; STATE MEDICINE;

EID: 33751221345     PISSN: 14753898     EISSN: None     Source Type: Journal    
DOI: 10.1136/qshc.2005.017061     Document Type: Review

References (39)

1. Petersen S. Coronary heart disease statistics. London: British Heart Foundation, 2005.
2. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004;109:1101-7.
3. Department of Health. National service framework for coronary heart disease: modern standards and service models. London: Stationery Office, 2000.
4. Roland M. Linking physicians' pay to the quality of care: a major experiment in the United Kingdom. N Engl J Med 2004;351:1448-54.
5. Heller RF, Buchan L, Edwards R, et al. Communicating risks at the population level: application of population impact numbers. BMJ 2003;327:1162-5.
6. Heller RF, Edwards R, McElduff P. Implementing guidelines in primary care: can population impact measures help? BMC Public Health 2003;3:art-7.
7. Gemmell I, Heller RF, McElduff P, et al. Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. J Epidemiol Community Health 2005;59:1041-6.
8. Department of Health. Health survey for England 1998. London: The Stationery Office, 1999.
9. Capewell S, Livingston BM, MacIntyre K, et al. Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J 2000;21:1833-40.
10. Mant J, Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ 1995;311:793-6.
11. Briggs A. Handling uncertainty in economic evaluation. BMJ 1999;319:120.
12. McPherson K, Britton A, Causer L. Coronary heart disease: estimating the impact of changes in risk factors, National Heart Forum. Norwich: The Stationery Office, 2002.
13. Primatesta P, Poulter NR. Lipid levels and the use of lipid-lowering agents in England and Scotland. Eur J Cardiovasc Prevent Rehabil 2004;11:484-8.
14. Primatesta P, Poulter NR. Hypertension management and control among English adults aged 65 years and older in 2000 and 2001. J Hypertens 2004;22:1093-8.
15. Shepherd J, Cobbe SM, Lorimer AR, et al. Compliance and adverse event withdrawal: their impact on the west of Scotland Coronary Prevention Study. Eur Heart J 1997;18:1718-24.
16. Walley T, Duggan AK, Haycox AR, et al. Treatment for newly diagnosed hypertension: patterns of prescribing and anti hypertensive effectiveness in the UK. J R Soc Med 2003;96:525-31.
17. Gibbs HD, Broom J, Brown J, et al. Current approaches to obesity management in UK primary care: the Counterweight Programme. J Hum Nutr Diet 2004;17:183-90.
18. Doll R, Peto R. Mortality in relation to smoking: 20 years observations on male British doctors. BMJ 1976;2:1525-36.
19. Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22.
20. Berlin JA, Colditz GA. A metaanalysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990;132:612-28.
21. Yusuf HR, Giles WH, Croft JB, et al. Impact of multiple risk factor profiles on determining cardiovascular disease risk. Prevent Med 1998;27:1-9.
22. Pereira MA, O'Reilly E, Augustsson K, et al. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med 2004;164:370-6.
23. Johansson S, Wilhelmsen L, Lappas G, et al. High lipid levels and coronary disease in women in Goteborg - outcome and secular trends: a prospective 19 year follow-up in the BEDA study. Eur Heart J 2003;24:704-16.
24. Psaty BN, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-44.
25. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7.
26. Ketola E, Sipila R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med 2000;32:239-51.
27. Baigent C, Sudlow C, Collins R, et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
28. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.
29. Ward S, Lloyd Jones M, Pandor A, et al. Statins for the prevention of coronary events. London: National Institute for Clinical Excellence (NICE), 2005.
30. Fox KM, Bertrand M, Ferrari R, et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
31. Critchley JA, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease (Cochrane Review). The Cochrane Library. Chichester: John Wiley & Sons, 2004.
32. Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112:298-304.
33. Jolliffe J, Rees K, Taylor R, et al. Exercise-based rehabilitation for coronary heart disease (Cochrane Review). The Cochrane Library. Chichester, UK: John Wiley & Sons, 2004.
34. HES Online. http://www.hesonline.nhs.uk (accessed March 2006).
35. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. Br Heart J 2005;331:614-9.
36. Rose G. Strategy of prevention - lessons from cardiovascular disease. BMJ 1981;282:1847-51.
37. Ebrahim S, Davey Smith G. Multiple risk factor intervention for primary prevention of coronary heart disease. Cochrane Collaboration. Chichester, UK: John Wiley & Sons, 2001.
38. Critchley JA, Capewell S. Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels. J Epidemiol Community Health 2003;57:243-7.
39. McElduff P, Lyratzopoulos G, Edwards R, et al. Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK. Qual Saf Health Care 2004;13:191-7.